TY - JOUR
T1 - Assessment of Patient-Derived Xenograft Growth and Antitumor Activity
T2 - The NCI PDXNet Consensus Recommendations
AU - Meric-Bernstam, Funda
AU - Lloyd, Michael W.
AU - Koc, Soner
AU - Evrard, Yvonne A.
AU - McShane, Lisa M.
AU - Lewis, Michael T.
AU - Evans, Kurt W.
AU - Li, Dali
AU - Rubinstein, Lawrence
AU - Welm, Alana
AU - Dean, Dennis A.
AU - Srivastava, Anuj
AU - Grover, Jeffrey W.
AU - Ha, Min J.
AU - Chen, Huiqin
AU - Huang, Xuelin
AU - Varadarajan, Kaushik
AU - Wang, Jing
AU - Roth, Jack A.
AU - Welm, Bryan
AU - Govinden, Ramaswamy
AU - Ding, Li
AU - Kaochar, Salma
AU - Mitsiades, Nicholas
AU - Carvajal-Carmona, Luis
AU - Herylyn, Meenhard
AU - Davies, Michael A.
AU - Shapiro, Geoffrey I.
AU - Fields, Ryan
AU - Trevino, Jose G.
AU - Harrell, Joshua C.
AU - Doroshow, James H.
AU - Chuang, Jeffrey H.
AU - Moscow, Jeffrey A.
N1 - Publisher Copyright:
© 2024 The Authors.
PY - 2024/7
Y1 - 2024/7
N2 - Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
AB - Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85198019118&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-23-0471
DO - 10.1158/1535-7163.MCT-23-0471
M3 - Article
C2 - 38641411
AN - SCOPUS:85198019118
SN - 1535-7163
VL - 23
SP - 924
EP - 938
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 7
ER -